% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Zhi:299509,
      author       = {Y. Zhi and S. E. Serfling and D. Groener$^*$ and P. E.
                      Hartrampf and T. Higuchi and M. Scheich and S. Hackenberg
                      and A. K. Buck and J. P. Steinbach$^*$ and R. A. Werner and
                      K. Klimek and M. Augustin},
      title        = {{S}omatostatin {R}eceptor-{D}irected {T}heranostics in
                      {E}sthesioneuroblastoma.},
      journal      = {Clinical nuclear medicine},
      volume       = {50},
      number       = {5},
      issn         = {0363-9762},
      address      = {Philadelphia, Pa.},
      publisher    = {Lippincott Williams $\&$ Wilkins},
      reportid     = {DKFZ-2025-00467},
      pages        = {363-367},
      year         = {2025},
      note         = {2025 May 1;50(5):363-367},
      abstract     = {We aim to report on somatostatin receptor (SSTR)-targeted
                      molecular imaging and therapy in patients with advanced
                      esthesioneuroblastoma (ENB).Five patients with ENB [Kadish
                      stage D in 5/5 $(100\%);$ Hyams grade 2 in 2/5 $(40\%),$
                      grade 3 in 2/5 $(40\%),$ undetermined in 1/5 $(20\%)]$
                      underwent SSTR-directed PET/CT. We quantified SSTR-avid
                      tumor volume (TV), maximum SUV (SUVmax), and
                      target-to-background ratios (TBR). Based on imaging, peptide
                      receptor radionuclide therapy (PRRT) along with dosimetry
                      was also conducted. We recorded nephrotoxicity and
                      hematotoxicity, including estimated glomerular filtration
                      rate (eGFR), hemoglobin, leukocytes, and thrombocytes at
                      baseline and after the last treatment cycle. We determined
                      adverse events following Common Terminology Criteria for
                      Adverse Events (CTCAE) v5.0. Response and progression-free
                      survival (PFS) was also evaluated.All 5 patients were rated
                      positive on SSTR-PET/CT. On a lesion-based level, we
                      identified 32 SSTR-avid tumor sites with a median TV of
                      11.7±10.8 and SUVmax of 24.3±12.8. TBR was 19.8±9.7,
                      indicating excellent image contrast. After median 4 (range,
                      2-6) cycles with a median of 7.7 GBq per cycle per patient,
                      we observed no CTCAE grade 3 or 4 toxicity for leukocytes
                      and thrombocytes and no significant CTCAE events for renal
                      function. One patient $(20\%),$ however, developed
                      reversible grade 3 anemia. Up to 11.8 Gy in tumor lesions
                      were achieved. Partial response was recorded in 3/5
                      $(60\%),$ stable disease in 1/5 $(20\%),$ and progressive
                      disease in 1/5 $(20\%).$ The median PFS was 29
                      weeks.SSTR-directed PET provided high image contrast in ENB,
                      suggesting good read-out capabilities in this tumor type.
                      PRRT was also feasible, along with an acceptable safety
                      profile, thereby rendering SSTR-targeted theranostics a
                      potential treatment option in advanced disease.},
      cin          = {FM01},
      ddc          = {610},
      cid          = {I:(DE-He78)FM01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40025672},
      doi          = {10.1097/RLU.0000000000005717},
      url          = {https://inrepo02.dkfz.de/record/299509},
}